Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients

Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients

Background Despite significant progress with antiprogrammed cell death protein 1 (PD-1) therapy, a substantial fraction of metastatic melanoma patients show upfront therapy resistance. Biomarkers for outcome are missing and the association of baseline immune function and clinical outcome remains to...

Full description

Bibliographic Details
Main Authors: Thierry Passeron, Alexandre Gérard, Jerome Doyen, Marion Cremoni, Laurent Bailly, Kevin Zorzi, Caroline Ruetsch-Chelli, Vesna Brglez, Alexandra Picard-Gauci, Laura Troin, Vincent L.M. Esnault, Henri Montaudié, Barbara Seitz-Polski
Format: Article
Language:English
Published: BMJ Publishing Group 2021-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/6/e002512.full

Internet

https://jitc.bmj.com/content/9/6/e002512.full

Similar Items